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Tuberculosis remains the most common cause of death due to a single infective organism.
Despite the availability of a vaccine and chemotherapeutic options, the global disease burden
remains relatively unaffected. The ability of the mycobacterial etiological agents to adopt a
semidormant, phenotypically drug-resistant state requires that chemotherapy is both complex
and lengthy. The emergence of drug resistance has raised the possibility of virtually
untreatable tuberculosis. Furthermore, the currently used bacillus Calmette–Guerin vaccine
has had mixed success in protecting susceptible populations. Given this backdrop, the need
for novel anti-infectives and more effective vaccines is clearly evident. Recent progress,
described herein, has seen the development and entry into clinical trials of several new drugs
and vaccine candidates.
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Members of the Mycobacterium tuberculosis
complex, the causative agents of TB, represent
some of the most successful human pathogens
affecting both developed and developing coun-
tries. It is estimated that a third of the global
population is a reservoir for these bacteria and
a record 9 million people developed active dis-
ease in 2004 [1]. M. tuberculosis is transmitted
by aerosols and, following inhalation, up to
50% of individuals exposed to the bacillus
become infected. Of these, only a fraction
(∼5%) develop TB, while the rest develop a
latent infection and may develop TB later
during their lifetime due to reactivation [2].
Current TB chemotherapy
Combination therapies have been used to
treat TB since p-aminosalicylic acid (PAS)
was successfully coadministered with strepto-
mycin to inhibit the emergence of strepto-
mycin-resistant strains [3]. After the first
national survey of UK drug resistance in the
mid-1950s showed that most drug-resistant
isolates were resistant to only one drug [4],
three-agent combination therapies were intro-
duced in which an initial three-drug phase
lasting for 2–3 months was followed by a
two-drug continuation phase.
The most common recommended stan-
dard chemotherapeutic regime for TB treat-
ment consists of an initial 2-month phase of
treatment with isoniazid (INH), rifampicin
(RIF), pyrazinamide (PZA) and ethambutol
(EMB), followed by a continuation phase of
treatment lasting 4 months with INH and
RIF [5]. INH and RIF represent the corner-
stones of anti-TB therapy; INH is the most
powerful mycobactericidal drug available,
reducing the bacterial population by approxi-
mately 95% over the first 2 days of treatment
and normally ensuring early sputum conver-
sion, thereby decreasing TB transmission as a
consequence. Despite this superlative early
bactericidal activity (EBA), it is no more
effective than other drugs after this initial
period. In cases where the disease presents as
a more chronic infection, the EBA of INH is
reduced markedly [6]. Following the initial
2 days of treatment, RIF becomes the most
significant bactericidal drug [6] and INH
serves to limit the emergence of RIF resis-
tance. The mycobactericidal activity of RIF
against sporadically active bacteria is crucial
for preventing relapses, and RIF in the con-
tinuation phase appreciably improves the
outlook for patients infected with an
INH-resistant strain [6].
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One of the major problems associated with the treatment of
TB is the bacterium’s penchant for adopting a nonreplicating
persistent state, probably induced by the prevailing environ-
mental conditions, a significant factor being a limiting supply
of oxygen [7–10]. Antibiotics are most effective against actively
growing M. tuberculosis rather than cultures in stationary phase
[11]. This antibiotic resistance shown by persistent
M. tuberculosis is not associated with any genetic changes but
with the adoption of a dormant metabolic state by the bacteria,
which may require special treatments and passage through liq-
uid culture before they can be cultured on agar plates. The
impact of this phenomenon in relation to clinical relapse is well
illustrated in the Cornell model of TB infection in mice [12,13].
After treatment with INH and PZA for 3 months,
M. tuberculosis cannot be detected in tissues of infected mice via
growth on agar plates. However, after treatment is withdrawn, a
third of the animals relapse within 3 months and, if immuno-
suppressed using steroids, almost all relapse. The recovered M.
tuberculosis clones display the same drug susceptibility as the
original infecting strain [12,13]. Owing to its apparent ability to
kill a subset of bacteria not killed by the other drugs, thought to
be sporadically active organisms subject to an hypoxic and pos-
sibly acidic environment [14–16], PZA represents an important
component of combination therapy; its inclusion has allowed
the shortening of the chemotherapeutic regimen to the current
6 months from an initial 9–12-month period.
The structures of the developing tuberculous lesions may
effectively define the metabolic status of their bacterial inhabit-
ants and it has been speculated that at least four significant sub-
populations of bacteria for which different drugs could be effi-
cacious exist. These might include active growers that may be
killed by INH, those with sporadic metabolic bursts that could
be killed by RIF, a population with low metabolic activity that
are considered likely to experience acidic surroundings and
hypoxia that may be susceptible to PZA and, finally, dormant
bacilli that are not killed by any current agents [14,17].
Emergence of drug resistance
Poor patient compliance is the major contributing factor in the
emergence of drug resistance and this is particularly relevant in
TB chemotherapy. The complex nature and length of the treat-
ment certainly contributed to unacceptable levels of noncompli-
ance. Likewise, logistical problems concerning drug supply and
the tendency for patients to feel well long before safe completion
of the prescribed course also contributed to an unacceptable
degree of noncompliance [18] promoting the emergence of drug
resistance and prompting the development of directly observed
treatment, short-course (DOTS) [19–21]. Initially, this acronym
described an intensively managed chemotherapy regime but has
since become used to describe a broader public-health strategy
that has been adopted in over 150 countries [21,22]. However,
over a quarter of the global population have no access to DOTS.
A Phase IV clinical trial of single-tablet combination therapy
with an initial intensive phase of 8 weeks of daily ethionamide
(ETH), INH, RIF and PZA, in a fixed-dose combined tablet,
followed by 18 weeks of RIF and INH, in a three-times weekly
fixed-dose combined tablet, has recently been completed. It is
to be hoped that this simplified regimen may go some way to
controlling the emergence of drug resistance.
Strains of M. tuberculosis resistant to both INH and RIF,
regardless of profiles of sensitivity/resistance to other drugs, have
been termed multidrug resistant (MDR). MDR-TB is a major
concern due to the associated high risk of death. While resis-
tance to either drug may be managed with other first-line drugs,
MDR-TB requires treatment with second-line drugs under
DOTS-Plus [5]. These agents often possess limited sterilizing
capacity and are not suitable for short-course treatment, necessi-
tating prolonged treatment with drugs that are less effective and
more toxic; several require injection [20,23,24]. The WHO cur-
rently recommends the use of a regimen including amikacin
(AMK), ETH, a fluoroquinolone (FQ; e.g., moxifoxacin
[MXF]) and PZA; in a mouse model, 9 months of this therapy
are needed to sterilize both lungs and spleen, while only
6 months are needed with the RIF plus INH plus PZA regimen
[25]. Recently, the emergence of extensively drug-resistant TB
(XDR-TB) strains, defined by the US CDC as those with resis-
tance to at least three of the six classes of second-line drugs
(aminoglycosides, polypeptides, FQs, thioamides, cycloserine
and PAS), has been reported [23]. In some regions, approaching
20% of MDR-TB cases were classified as XDR-TB, raising con-
cerns over a future epidemic of virtually untreatable TB [23].
New drug ‘pipeline’ in TB therapy
Given this backdrop, the need for rapid and continued progress
in the development of new lead compounds and the identifica-
tion and characterization of novel drug targets to engage medic-
inal chemists is clearly evident. A crucial consideration for new
agents is their effectiveness in coadministration with antivirals
used to treat HIV [19,26,27]; rifamycins, such as RIF, activate
human cytochrome P450, which metabolize antivirals, signifi-
cantly reducing their plasma concentrations [27]. Fortunately,
several promising anti-TB agents are currently at various stages
of development; some are analogues or derivatives of current
first- and second-line anti-TB agents, such as quinolones and
EMB, while others have been discovered through extensive
screening programs or from screening of focused libraries
designed with particular targets in mind.
Classes of agents with representatives in clinical trials
Ethambutol derivative SQ109
The front-line anti-TB agent EMB inhibits cell wall arabinan
biosynthesis in both the structural polysaccharide arabino-
galactan [28,29] and the wall-associated lipoglycan, lipoarabino-
mannan [29]. An EMB derivative, N-geranyl-N´-(2-adaman-
tyl)ethane (SQ109) exhibited improved activity against
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M. tuberculosis compared with EMB, their respective mini-
mum inhibition concentrations (MIC) were recorded as 0.5
and 5.0 µg/ml [30,31]. Encouragingly, SQ109 is also more
potent than EMB against mycobacteria within macrophages
and mice [30]. Analysis of M. tuberculosis H37Rv transcriptional
profiles after several different drug treatments revealed that,
despite many similarities, SQ109 and EMB differentially
affected a regulon containing genes implicated in fatty acid
modification and in the biosynthesis of the essential cell wall
components, the mycolic acids. This apparent mechanistic
divergence was confirmed by the observation that, unlike their
SQ109-treated counterparts, the wall of M. tuberculosis treated
with EMB rapidly lost their acid-fast staining properties and
contained significantly less arabinose than controls [32].
Despite low bioavailability after oral administration [30],
SQ109 was entered into Phase I clinical trials. Recently, both
US FDA and EMEA awarded sequella orphan drug and
orphan medicinal product status allowing 7 years of market
exclusivity for the use of SQ109 in TB treatment. This status
provided under the Orphan Drug Act provides economic
incentives to encourage the development of drugs for diseases
affecting fewer than 200,000 people in the USA.
Quinolones
Quinolones target bacterial type II topoisomerases, DNA
gyrase and topoisomerase IV [33,34]. These ATP-dependent
enzymes cooperate to facilitate DNA replication and other
key DNA transactions [35]. DNA gyrase is involved in cata-
lyzing the negative supercoiling of DNA, is essential for
DNA replication, recombination and transcription and
appears to be the sole topoisomerase target for quinolones in
M. tuberculosis [36].
Of the series of developed quinolone derivatives, FQs have
shown a broad spectrum of antibacterial activity. FQs have
been used sparingly due to the frequent emergence of resistance
to the readily available derivatives, ofloxacin and ciprofloxacin
[37]. New FQs containing a C-8 methoxy moiety exhibit greater
activity and two compounds in particular, MXF and gatifloxa-
cin (GAT) (FIGURE 1A), showed good activity in murine models of
TB [38–41]. MXF is more active than ofloxacin and ciprofloxi-
cin; they require MICs of 0.125, 2 and 4 µg/ml, respectively
[40]. In a mouse model, MXF activity against M. tuberculosis is
comparable to INH [39,40] and, encouragingly, MXF also
appeared to kill a subpopulation of RIF persistors [42]. Further-
more, inclusion of MXF in a combination regime greatly
reduced time to culture conversion in murine TB. A combina-
tion of RIF plus PZA plus MXF was more effective than INH
plus RIF plus PZA [43,44], presenting the possibility that MXF
might replace INH in a combination regime to shorten TB
therapy in humans. However, concerns over the potential toxic-
ity of RIF plus PZA combinations in the absence of INH have
been highlighted by the incidence of fatal and severe liver inju-
ries associated with treatment of latent TB infections with RIF
plus PZA [45,46].
Several FQs are now in clinical trials. MXF, GAT and high-
dose levofloxacin, the potent L-stereoisomer of the ofloxacin
racemate, all showed excellent EBA approaching that of INH
[47,48]. Encouragingly, a more potent extended EBA, that is,
from days 2 to 7, was observed with the FQs than for INH [47].
A recent Phase II trial to investigate whether MXF could
replace EMB in INH plus PZA plus RIF plus EMB combina-
tions revealed that, although the MXF regimes showed more
frequent sputum conversion at 4 weeks, the success of the
treatments provided identical outcomes after 2 months [49].
The 2-month timepoint coincides with the end of the inten-
sive phase of treatment with common regimens, and culture
conversion rates at this stage are a well-accepted surrogate
marker for the sterilizing activity of anti-tuberculosis drugs.
We await the publication of data from a recently completed
Phase II trial to determine whether substitution of MXF for
INH will improve rates of sputum conversion at this 2-month
stage; significant improvement here would support the case for
Phase III trials of MXF-containing regimens of under
6 months total duration. A Phase III clinical trial aimed at
assessing the success of a 4-month GAT-containing regimen is
now recruiting participants. Various trials are also underway to
assess the influence of RIF (Phase II)/rifapentine (Phase I)
coadminstration upon MXF pharmacokinetics.
Recently, 16 7-substituted GAT derivatives were tested for
antimycobacterial activity in vitro and in vivo against
M. tuberculosis H37Rv and MDR M. tuberculosis [50]. Four
compounds were more active (MIC < 0.2 µg/ml) and five
compounds were equipotent (MIC: 0.2 µg/ml) to GAT
against M. tuberculosis. The most active compound, 1-cyclo-
propyl-6-fluoro-8-methoxy-7-[[[N4-[1´-(5-isatinyl-β-semicar-
bazo)]methyl]N1-piperazinyl]4-oxo-1,4-dihydro-3-quinolone
carboxylic acid, exhibited an in vitro MIC of 0.0125 µg/ml
against M. tuberculosis and MDR-TB strains. In the intra-
venously infected mice, the compound decreased the bacterial
load in lung and spleen tissues by 3.26 and 3.76 logs, respec-
tively, indicating that increasing the length of the lipophilic
side chain at C-7 improves the antimycobacterial activity
in vitro [50]. With this in mind, appropriate modification of
MXF, which is more effective than GAT, could provide more
effective inhibitors of DNA gyrase with improved efficacy.
Diarylquinoline TMC207
The antimycobacterial activity of diarylquinolines (DARQs)
was identified via screening prototypes of different chemical
series for inhibition of the growth of the fast-growing sapro-
phyte Mycobacterium smegmatis. Lead optimization generated a
series of 20 promising DARQs expressing potent in vitro activ-
ity against several mycobacteria, including M. tuberculosis [51],
with three exhibiting encouraging in vivo activity. The MIC for
the most potent of these, TMC207 (formerly R207910
FIGURE 1B), was 0.03 µg/ml for M. tuberculosis [51] with similar
in vitro efficacy against M. tuberculosis clinical isolates resistant
to INH, RIF, streptomycin, EMB, PZA and MXF [51,52]. This
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lack of crossresistance with currently used anti-TB agents sug-
gested that TMC207 retains activity against MDR strains and
exerts its antimycobacterial effect through a novel cellular tar-
get. Consistent with this, TMC207-resistant spontaneous
mutants of M. tuberculosis had no crossresistance with other
anti-TB agents [51]. A role for the product of atpE, a compo-
nent of the mycobacterial F1F0 ATP synthase, in resistance to
DARQs has been demonstrated [51]. Mutations in its mem-
brane-spanning region confer resistance to TMC207, implying
that the atpE gene product is the primary target of TMC207 in
mycobacteria. Recently, a study of susceptibility of a panel of
various mycobacteria including susceptible and resistant TB,
representatives of the Mycobacterium avium complex and a wide
range of other nontuberculous mycobacte-
ria confirmed the drug’s broad antimyco-
bacterial spectrum and also correlated the
natural resistance of Mycobacterium xenopi,
Mycobacterium novocastrense and Mycobac-
terium shimoidei with a methionine for ala-
nine substitution near a substrate-binding
site of ATP synthase [52].
In TMC207 monotherapy, a potent
EBA comparable to that of INH was
observed in a nonestablished infection
murine TB model in which treatment
began on the first day of the infection
study. Furthermore, a late bactericidal
effect exceeding that of RIF was also
observed in the established infection
murine TB model, in which treatment
commenced on the 12th day of infection
[51]. However, as TMC207-resistant
mutants emerge at a frequency compara-
ble to RIF-resistant mutants in vitro,
DARQ monotherapy is contraindicated.
Despite this, TMC207 appears to be a
useful component for combination ther-
apy. Substitution of each of RIF, INH and
PZA with TMC207 resulted in a signifi-
cant increase in potency, leading to com-
plete culture conversion of the lungs in
some animals after 1 rather than 2 months,
indicating potential for reducing the
length of combined therapy [51].
Recently, a study in mice to define the
optimal TMC207-containing regimen to
treat MDR-TB identified for the first time
a regimen without INH and RIF that was
able to sterilize the lung and spleen within
2 months [53]. Administered along with
AMK plus ETH plus MXF plus PZA,
TMC207 appeared to accelerate bacterial
clearance from mice, supporting the possi-
bility of the drug shortening treatment
duration in humans. However, further studies to assess various
combinations of TMC207 with AMK, MXF, ETH and PZA are
needed to define their individual contributions to this therapy. In
addition, relapse rates with the most promising combinations
need to be determined to fully understand the potential of these
new regimens.
TMC207 is well tolerated in humans, at least during a lim-
ited exposure period, with plasma levels approximately eight-
fold greater than those associated with potent in vivo activity in
mice and only mild or moderate adverse effects [51]. Patients
with MDR-TB are currently being recruited to a Phase II clini-
cal trial to assess antibacterial activity, safety and tolerability of
TMC207 in combination therapy.
Figure 1. Some promising drug candidates with activity against 
Mycobacterium tuberculosis.
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Nitroimidazopyran PA-824
The nitroimidazopyran PA-824 (FIGURE 1D) represents a promising
new compound for the treatment of TB that is currently under-
going human trials. Similar to its progenitors metronidazole and
CGI-17341, PA-824 is a nitroimidazole prodrug, requiring
bioreductive activation of an aromatic nitro group to exert its
anti-tubercular effect [54]. PA-824 activation requires the bacte-
rial F240-dependent glucose-6-phosphate dehydrogenase
(FGD1) and nitroreductase and the protein product of Rv3547
[55] to inhibit mycolic acid and protein synthesis. PA-824 is
highly active with a MIC as low as 0.015–0.025 µg/ml against
M. tuberculosis and MDR-TB. In preclinical testing against a
broad panel of MDR clinical isolates in vitro, PA-824 was highly
active against all isolates with MICs less than 1 µg/ml [56]. In a
short-course mouse infection model, the efficacy of PA-824 was
comparable to INH, RIF and MXF. PA-824 also exhibited
potent activity during the continuation phase of therapy, during
which it targeted bacilli that had persisted through an initial 2-
month intensive phase of treatment with RIF, INH and PZA
[57]. We await the outcome of a recently completed Phase IIa trial
to evaluate the safety, tolerability, extended EBA and pharma-
cokinetics of PA-824 against newly diagnosed, uncomplicated,
adult pulmonary TB in South Africa. The TB Alliance has also
initiated an investigation of PA-824 nitroimidazole analogs.
Dihydroimidazo-oxazole OPC-67683
A further azole-based lead compound is currently in Phase II
studies [58]. The compound is also a mycolic acid biosynthesis
inhibitor possessing potent activity against TB, including MDR-
TB, with an exceptionally low MIC in the range of 0.006–0.024
µg/ml in vitro and highly effective therapeutic activity at low
doses in vivo [59]. In addition, a significant post-antibiotic effect,
that is, an extended period of inhibition after the plasma concen-
tration is exceeded by MIC, was observed against intracellular M.
tuberculosis H37Rv when OPC-67683 was removed after 4 h
exposure. In this situation, its potency at 0.1 µg/ml was similar to
that of the first-line drug RIF at 3 µg/ml. Combination of OPC-
67683 with RIF and PZA resulted in a quicker eradication of via-
ble TB bacilli in the lung in comparison with the standard regi-
men of RIF plus INH plus PZA plus EMB. Furthermore, OPC-
67683 was not affected by nor did it affect the activity of liver
microsome enzymes, suggesting the possibility for OPC-67683
to be used in combination with drugs, including antiretrovirals,
that induce or are metabolized by cytochrome P450 enzymes. As
with PA-824 [60], this azole drug also requires reductive activation
that appears to be mediated through Rv3547 [59].
We await the publication of the findings of a completed Phase II
clinical trial addressing the safety, efficacy and pharmacokinetics of
OPC-67683 in patients with uncomplicated pulmonary TB.
Sudoterb (pyrrole LL-4858)
Sudoterb was reported to have potent anti-TB activity in vitro
and in vivo (mice and guinea pig) studies. In vitro, sudoterb
has bactericidal activity similar to INH and is synergistic with
RIF [61]. The combination of sudoterb with INH plus RIF plus
PZA led to complete sterilization of sensitive and MDR-TB
strains in infected mice within 2 months. In combination with
RIF plus PZA, sudoterb also cured TB in all animals after
3 months of treatment, presenting the possibility that it might
significantly shorten TB treatment in combination therapy [62].
As for MXF, the safe use of RIF plus PZA combinations without
INH must be assessed.
Oxazolidinones
Oxazolidinones inhibit protein synthesis by selectively and
uniquely binding to the 23S rRNA of the 50s ribosomal
subunit [63]. They possess antimicrobial activity against a
variety of Gram-positive bacteria, including M. tuberculosis,
with a MIC of 2–4 µg/ml and are also active against tubercle
bacilli in mice [64–66]. Three clinical candidates, eperezolid,
linezolid and PNU-100480, a thiomorpholine analogue of
linezolid, were identified as antimycobacterial agents [67].
PNU-100480 exhibited an MIC90 of 0.9–2.5 µM against
M. tuberculosis in vitro [67] and comparable activity in vivo to
that of INH and RIF in a murine model [68]. More recently,
the antimycobacterial activity of 3-(1H-pyrrol-1-yl)-2-oxazo-
lidinones analogues RBx 7644 and RBx 8700 was estab-
lished [69]. RBx 8700 demonstrated good in vitro activity
against drug-sensitive, as well as MDR-TB, strains with
MIC90 values of 0.25 µg/ml (sensitive) and 1.0 µg/ml
(MDR strains), respectively. The MIC90 for RBx 7644 and
linezolid was 16 and 64 µg/ml, respectively [69]. As RBx
8700 showed promising activity and a good correlation
between MIC values in vitro and in a macrophage system, fur-
ther study of RBx 8700 in experimental models of M. tubercu-
losis to determine its full potential as a possible anti-TB drug
is warranted.
Linezolid has recently been approved by the FDA for the
treatment of MDR Gram-positive bacterial infections [63].
However, clinical studies have shown that prolonged use of
linezolid in the treatment of MDR-TB caused frequent sig-
nificant toxicity, including anemia, bone marrow depression
and potentially irreversible peripheral neuropathy [70,71].
Recently, the first linezolid-resistant clinical isolates of
M. tuberculosis have been described [72]. Genetic analyses
revealed no mutations in potential target genes, including
the 23S rRNA gene, the rplV and rplD genes, encoding ribo-
somal proteins L4 and L22, respectively, the erm-37 gene,
encoding a 23S rRNA methyltransferase, and whiB7, which
encodes a putative regulator. The mechanism of resistance is,
therefore, unclear but may be related to the efflux rate [72].
Agents in preclinical development
Encouragingly, many agents are currently showing promise
toward potential use in TB chemotherapy. Here, we describe
several of these; a more comprehensive list can be found using
StopTB [201] and TB Alliance [202].
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Azoles 
Azoles are commonly used antifungal agents, some of which
have been shown to have antimycobacterial activity [73,74]. The
recent recognition of a plethora of cytochrome P450s, known
cellular targets of azoles in fungi [75,76], encoded in the
M. tuberculosis genome [77] drove studies to examine the corre-
lation between the presence of P450 and the susceptibility to
azole drugs in M. tuberculosis [78–80]. Purified MTCYP51, a
M. tuberculosis cytochrome P450, was found to bind azoles
tightly, providing biochemical evidence that azole drugs might
also inhibit mycobacterial P450 enzymes. Two azoles, clotrima-
zole and econazole (FIGURE 1C), were tested for their antimycobac-
terial activity against M. tuberculosis H37Rv. The MIC90 was
0.12 µg/ml, whereas the minimum bactericidal concentration
was 0.125 µg/ml for both drugs, demonstrating their excellent
bactericidal activities [81]. Ex vivo studies on mice splenocytes
following exposure to clotrimazole and econazole confirmed
the good tolerance and synergistic effects of these drug [82]. Fur-
ther in vivo analyses have determined that econazole is well tol-
erated in combination therapies and equipotent to RIF in the
treatment of murine TB [83]. The crystal structure of
MTCYP51 with bound azoles has recently been elucidated and
is being probed for development of novel drug therapies against
TB [84,85]. 
N-alkylsulphonylacetamides
β-ketoacyl-acyl carrier protein (ACP) synthases play an impor-
tant role in the biosynthesis of fatty acids, the mycolic acid com-
ponents of the cell wall and various virulence-related polyketides
in pathogenic mycobacteria. β-sulphonylcarboxamide com-
pounds were designed as mimics of the reactive acetyl enolate
intermediate in the condensation reaction these enzymes cata-
lyze [86]. The most potent antimycobacterial compounds discov-
ered through this strategy were amide derivatives of 3-sulphonyl
fatty acids bearing alkyl chains of between eight and ten carbons
in length; MICs as low as 0.75 µg/ml are comparable to front-
line anti-TB agents. Surprisingly, the activity profile of these
compounds was particularly species dependent, they exhibit no
significant activity against bacteria other than M. tuberculosis
and closely related strains, including nonpathogenic mycobacte-
ria [86]. One of these, N-octanesulphonylacetamide (OSA), was
tested further against several pathogenic and drug-resistant
mycobacteria, including MDR-TB, strains [87]. Analysis of lipid
biosynthesis after exposure to OSA revealed a marked inhibition
of mycolic acid biosynthesis in Mycobacterium bovis BCG with
no alteration in the panoply of other complex lipids generated
by the bacterium; mycolic acid biosynthesis in the relatively
insensitive M. smegmatis was unaffected [87]. Electron micros-
copy of treated sensitive bacteria revealed dysfunction in cell
wall biosynthesis and incomplete septation [87]. The over-
production in OSA-treated M. bovis BCG of the β-subunit of
F1F0 ATP synthase encoded by atpF [88] suggested the involve-
ment of ATP synthase, either directly or indirectly. Consistent
with atpF overexpression, cellular ATP levels decreased upon
treatment with OSA [88]. Reminiscent of TMC207, this OSA-
mediated decrease in cellular ATP may signal the inhibition of
the F1F0 complex or may target other unidentified regulatory
components involved in energy production.
Recently, the developers of OSA, FASgen Inc. (MD, USA),
announced 3-sulfonyltridecanamide (FAS20013) as their lead
proprietary compound for the treatment of TB and MDR-TB
[89]. It exhibits potent bactericidal activity for anaerobically
adapted M. bovis BCG, that is, against anaerobically nonrepli-
cating persistence, and coresistance to established agents has
not been reported in clinical isolates [89].
Phenothiazines
The antimycobacterial activity of phenothiazines has been
reported sporadically over the past 40 years [90–92]. One such
phenothiazine, trifluoroperazine (TPZ), exhibited a significant
effect on in vitro ATP synthesis in Mycobacterium leprae [93]. An
insight into the mode of action of TPZ was gained through the
discovery that cellular ATP levels in M. leprae were dramatically
reduced in the presence of the drug, suggesting a target in the
mycobacterial oxidative phosphorylation system. A thorough
biochemical analysis implicated type II NADH: menaquinone
oxidoreductase (NDH-2) as the target of TPZ in M. tuberculo-
sis [94]. The bacterium possesses a branched respiratory chain
with specific termini induced under aerobic or microaerobic
conditions [94,95] but both chains are initiated by NDH-2. The
essential role of NDH-2 in M. tuberculosis is supported by bio-
chemical studies, transcriptional studies, gene-deletion analy-
sis, investigations of bacterial growth in various culture condi-
tions and animal experiments [32,94]. TPZ and its analogue
chlorpromazine are effective against M. tuberculosis H37Rv in a
macrophage model of infection, and are synergistic with both
INH and RIF [96,97]. The poor pharmacokinetics for TPZ
result in a large (>100-fold) disparity between the minimal bac-
tericidal concentration in vitro and concentrations achievable
in vivo [97], thus 50 analogues were screened for greater
potency. Three showed potential, with the most active having a
MIC of 1.11 µg/ml in comparison with those for TPZ
(19.2 µg/ml), RIF (0.5 µg/ml) and INH (0.15 µg/ml). Encour-
aging activity in a mouse model of acute infection reducing the
bacterial load within the lungs and spleen established it as a
potential lead for drug development [94].
Peptide deformylase inhibitor BB-3497
Bacterial peptide deformylase (PDF) is a metalloprotease that
removes the N-terminal formyl group from newly synthesized
proteins. Various PDF inhibitors have activity against several
pathogens, including Escherichia coli and Staphylococcus aureus,
in vitro [98–100]. Six PDF inhibitors were screened against two
isolates of M. tuberculosis and initial testing showed that three
compounds, BB-3497, BB-84518 and BB-83698, exhibited
MICs in the range of 0.06–2 µg/ml [101]. These were further
tested against 17 isolates of M. tuberculosis and BB-3497 was
the most active with a median MIC of 0.25 µg/ml. Further
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in vivo evaluation is required to fully determine the potency of
BB-3497 and clinical tests must be carried out that address
whether the drug is toxic in humans. A recent study suggested
that PDF inhibitors had no detectable effect on two different
human cell lines in vitro [102].
Acetohydroxyacid synthase inhibitor KHG20612
Acetohydroxyacid synthase (AHAS) catalyses the first common
step in the biosynthesis of branched amino acids leucine, iso-
leucine and valine [103,104]. The AHAS encoded by ilvB and
ilvN in M. tuberculosis was overproduced in E. coli and purified
to homogeneity [105]. A microplate-based enzyme assay was
developed to screen small molecules as potential inhibitors of
the catalytic subunits of AHAS from a chemical library com-
posed of 5600 compounds. Library screening identified four
structurally related hit compounds that inhibited AHAS activ-
ity by more than 90% at 40 µM. These compounds were func-
tionally related, bearing a disulfide bond and containing a phe-
nyl or 1-substituted triazolyl groups. A range of IC50 values of
1.8–2.6 µM was reported for these four compounds.
KHG20612 also inhibited growth of various drug-resistant
strains of M. tuberculosis [105]. 
Thiolactomycin
Thiolactomycin (TLM) is a thiolactone antibiotic (FIGURE 1E)
isolated from a soil Nocardia spp. [106]. TLM exhibits potent
in vitro activity against many pathogenic bacteria, including
Gram-negative and Gram-positive bacteria and M. tuberculo-
sis. TLM inhibits the β-ketoacyl-ACP synthase condensing
enzymes mtFabH and KasA of the FAS-II system in M. tuber-
culosis [107,108], which are involved in the synthesis of the
essential mycolic acids of the cell wall. In vitro and in vivo
inhibition of mtFabH and KasA leads to the inhibition of
mycolic acid biosynthesis. The total synthesis of TLM was
first reported by Wang and Salvino [109] and was improved to
yield the active 5R stereoisomer [110]. Several analogues have
since been designed and tested against M. tuberculosis
[60,111–115]. Preliminary studies showed that modifications to
the thiolactone core in the C-5 position with a 5-tetrahydrog-
eranyl substituent gave an MIC90 of 29 µM and 92% inhibi-
tion in extracts of M. smegmatis, compared with 125 µM and
54%, respectively, for TLM [115]. As a continuation to these
studies, a series of C-5 substituted biphenyl and acetylene ana-
logues were developed and two compounds showed a marked
increase in an in vitro assay against mtFabH [112,113]. 5-[3-(4-
acetyl-phenyl)-propyl-2-ynyl]-4-hydroxy-3,5-dimethyl-5H-
thiophen-2-one and 5-(4´-benzyloxy-biphenyl-4-yl-methyl)-
4-hydroxy-3,5-dimethyl-5H-thiophen-2-one gave an 18-fold
and fourfold increase in activity with an IC50 value of 17 and
4 µM, respectively, compared with 74.9 µM for TLM. By
contrast, others have suggested that C5 substitutions of the
TLM core renders the analogues inactive against M. tuberculo-
sis [60]; this matter awaits clarification. However, the recent
determination of the crystal structure of M. tuberculosis KasB
and subsequent homology modeling of KasA, using the KasB
structure as a template, supports the potential for C5-derivati-
zation of the TLM scaffold towards the design of improved
antimycobacterial KAS inhibitors [116].
Siderophore biosynthesis 
Siderophores are ferric ion-specific chelating agents elaborated
by various aerobic bacteria to assimilate iron [117]. Although the
metal might be plentiful, as in the tissues of pathogen-infected
host organisms, it is sequestered and hence not readily available
to them [117]. Siderophores can remove iron from insoluble
inorganic polymers or from eukaryotic proteins and are com-
monly recognized as virulence factors of important bacterial
pathogens, although some pathogens use alternate acquisition
mechanisms [117]. M. tuberculosis produces two biosynthetically
related siderophores: carboxymycobactins that operate in the
normal extracellular mode, returning chelated iron to the bac-
terium from its environment; and mycobactins that are unique
among bacterial siderophores in remaining cell bound [117].
Both types of siderophores have identical iron-binding centers
and differ only in their long acyl chains, the water soluble car-
boxymycobactins bear a terminal carboxylic acid group absent
in the cell-bound mycobactins [117]. Several of the genes associ-
ated with the synthesis of the mycobactin core have been iden-
tified in the ten-gene mbt cluster [118] and a further cluster
recently designated mbt2 [119,120]. Component genes of both
clusters are essential for the in vivo growth of M. tuberculosis
[121–123] and expression is regulated by iron availability.
The first committed steps towards the biosynthesis of the
iron-binding center of the (carboxy)mycobactins is the MbtA-
catalyzed adenylation of salicylic acid, which activates the aryl
acid for its subsequent transfer to a phosphopantetheinyl-serine
residue of MbtB for its subsequent ligation with serine or thre-
onine [118]. Recently, two groups designed analogues of the sali-
cyloyl-AMP intermediate incorporating stable bioisosteres to
replace the labile phosphate moiety. These showed good activ-
ity against M. tuberculosis grown under iron-limiting conditions
[124,125] at low micromolar concentrations. Especially impres-
sive was an analogue in which the phosphoryl moiety was
replaced with a sulphamide that exhibited an MIC for
M. tuberculosis of 0.19 µM [124].
Purine analogues
Recently, the screening of novel compounds has highlighted
modified purines as potential antimycobacterial drugs [126–129].
Screening of a library of 6-substituted and 2,6-di-substituted
9-benzyl-purines revealed several compounds with encouraging
activity against M. tuberculosis, with a general trend suggesting
that 6-substituted varieties were more effective than their dis-
ubstituted counterparts, although chlorination at the 2 position
did tend to increase activity [126]. 2-monosubstituted library
members possessed no anti-TB activity. High inhibitory activ-
ity was found for those carrying phenylethynyl-, trans-styryl or
aryl substituents in the 6 position; the most active bears a furyl
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substituent with MICs as low as 0.78 µg/ml, comparable to
that for RIF, and representing a good lead. In order to optimize
the N-9 substituent, a library of 6-aryl, 9-alkyl-purines was syn-
thesized and screened, confirming that the N-9 benzyl substitu-
ent used in the previous study showed greatest activity [128].
More extensive testing revealed that the 6-furyl derivative
exhibited low cytotoxicity for Vero cells, retained activity
against several singly drug-resistant strains of M. tuberculosis
and was active (MIC: 8.46 µg/ml) against M. tuberculosis
Erdman in bone marrow macrophages [128].
Further active 6,9-di-substituted purines with significant
activity against M. tuberculosis were generated by reacting
6-mercaptopurine with sulphonyl/sulphenyl halides [127]. Sev-
eral compounds had low MICs between 0.39 and 3.9 µg/ml for
M. tuberculosis H37Rv. Screening of two classes of derivative
against M. tuberculosis strains resistant to nine of the main clin-
ically used antimycobacterial agents revealed that extensive
crossresistance with several of these agents, one showed little
crossresistance and thus was identified as having great potential
as a lead compound [127].
Screening of another library of 6-thiopurines incorporating
6-thioaryl/alkyl-urines, 2-thioaryl/alkyl-pyrimidines and 2- and
4-thioaryl/alkyl-pyridines identified highly active compounds
9-(ethylcarboxymethyl)-6-(decylthio)-9H-purine and 9-(ethyl-
carboxymethyl)-6-(dodecylthio)-9H-purine with MICs of 1.56
and 0.78 µg/ml, respectively, against M. tuberculosis H37Rv with
the former showing good activity against the Erdman strain in
bone marrow macrophages [129]. Together, these various studies
demonstrate that further development of these purine derivatives
may generate interesting novel anti-TB agents.
M. tuberculosis immunology & vaccines
Following entry into the respiratory tract, the TB bacillus is
phagocytosed by alveolar macrophages. Once inside the mac-
rophage phagosome, the bacterium evades the usual post-
phagocytic defense mechanisms by using a range of evasive tac-
tics, which include altering the endosomal pH (inhibiting
phagolysosome acidification) [130,131], detoxification of harmful
radicals and inhibition of apoptosis [131]. This is followed by a
stage of rapid intracellular mycobacterial replication. The bac-
teria are then taken up by dendritic cells, which transport them
to the adjacent lymph nodes. Antigen presentation causes a
Th1-type immune response and this results in the formation of
granulomas at the primary site of infection in the lung. The
granuloma is not only thought to prevent dissemination but to
also facilitate a microenvironment for immune cell communi-
cation that may result in bactericidal activity in the lesion. Cru-
cial to this complex response is the synergy between the cyto-
kines IFN-γ and TNF-α [132] that results in killing of
M. tuberculosis by macrophage activation and by cytolysis. A
complex set of T cells (CD4+, CD8+, γδ and CD1-restricted
αβ T cells) are involved in containing the infection [133]. How-
ever, in many cases, infection is not contained, resulting in
caseous necrosis, active clinical disease and the infected individ-
ual becoming capable of transmission. On the other hand,
when the tubercle bacillus is contained within a granuloma, the
bacteria can remain in a dormant state for decades, resulting in
latent TB. Reactivation may occur at a later stage due to a
weakened or compromised immune system.
Despite the demonstration of the etiological agent of TB
more than a century ago, there is no effective prophylactic vac-
cine available. Bacille Calmette–Guerin (BCG), an attenuated
strain of the bovine TB bacillus M. bovis used globally, has had
mixed success, ranging from excellent protection to none at all
[134]. Variations in protection depend on different factors, such
as age and geographical location, and the protective effect of
BCG vaccination has been known to wane over time [135]. For
a while, an emphasis for new candidate vaccines has been for a
prophylactic (pre-exposure) vaccine; a better understanding of
the pathogenesis of M. tuberculosis, latency and the immune
response to TB has led to the idea of a post-exposure, thera-
peutic vaccine that would be able to not only induce a protec-
tive response in exposed individuals but also target dormant
bacteria, thus preventing latency [136]. This is particularly rele-
vant in the light of recent immunological studies on antigens
expressed by the dormancy (DosR) regulon: tuberculin test-
positive individuals recognized more latency antigens and with
a stronger IFN-γ response than TB patients [137]. Furthermore,
BCG vaccination failed to induce significant responses to
latency antigens [138].
This part of the review will deal with the newer approaches
toward development of effective TB vaccines. There are currently
three main strategies employed by researchers: 
• Improving the existing BCG strain as a vaccine
• Development of live-attenuated M. tuberculosis strains
• The use of ‘nonbacterial’ vaccines, such as viral delivery vectors,
DNA and subunit vaccines
Improving BCG vaccination
A number of suggestions have been made to explain the varying
efficacy of BCG as a vaccine, including the loss of protective
antigens from BCG and an inadequate T-cell response against
BCG [139]. To overcome the former, a number of research
groups have overexpressed immunodominant antigens of
M. tuberculosis into existing BCG vaccine strains [139]. These
include recombinant BCG strains expressing antigen 85B (a
highly immunogenic, secreted mycobacterial protein involved
in cell wall biosynthesis) or  early secreted antigenic target
6-kDa protein (ESAT-6), which gave better protection than
BCG in animal challenge models [140–142].
Class I-restricted CD8 T cells play an important role in con-
taining TB infection. Apoptosis is one of the main inducers of
cell-mediated immunity and antigens contained in apoptotic
vesicles play an important role in MHC class I restriction of
CD8 T cells [143,144]. As a part of its immune evasion strategy,
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the TB bacillus causes inhibition of apoptosis of infected host
cells, thereby reducing class I presentation. A similar inhibition
of apoptosis was also observed for BCG-infected cells [145], sug-
gesting that this property of BCG may be one of the factors
responsible for the poor efficacy of the strain as a vaccine.
Recombinant BCG strains that induce apoptosis have also been
evaluated as vaccines (reviewed in [139]): strains expressing a
recombinant listeriolysin (pore-forming cytolysin from Listeria
monocytogenes) led to an increased presence of cytoplasmic BCG
(due to pore formation in the phagosome) and a resultant
induction of apoptosis [146]. Recently, Hinchey et al. demon-
strated that inactivation of secA2, a secretion system component,
resulted in enhanced apoptosis of infected macrophages and
increased priming of specific CD8+ T cells in vivo [147]. Mice
and guinea pigs vaccinated with the mutant strain showed
increased resistance to M. tuberculosis challenge than those
infected with BCG [147]. These studies demonstrated that both
recombinant, apoptosis-inducing BCG strains and avirulent
M. tuberculosis mutants that have lost an apoptosis-inhibiting
component have potential use as live vaccines due to their ability
to cause enhanced MHC class I presentation. 
Attenuated M. tuberculosis strains as live vaccines
The motivation behind using attenuated M. tuberculosis strains
is that these strains are based on the actual causative agent
rather than a related bovine strain and thus would be closest to
mimicking the immune response to TB. Furthermore, there are
an additional 120 M. tuberculosis genes that are absent in BCG
[148,149]. Rather than using extended serial passage to achieve
attenuation, as was the case for BCG, the rationale is to use
mutants of M. tuberculosis that contain deletions in genes essen-
tial for virulence. The key to the success of such a vaccine is
achieving the right balance between loss of virulence and gener-
ating an effective immune response against the attenuated
strain (i.e., achieving a ‘safe’ level of attenuation without much
loss of immunogenicity). 
However, there are obstacles to using M. tuberculosis-attenu-
ated mutant strains as vaccines. First, there is a risk of reversion;
however, this risk can be greatly reduced by generating strains
that have at least two independent deletions in known virulence
genes. Furthermore, these strains would need to be unmarked,
that is, any antibiotic resistance markers used for selection of
mutants must be subsequently removed. Finally, the safety of
these strains would need testing in immune compromised
animal models.
One promising candidate is a phoP mutant (PhoP is a tran-
scription factor); although attenuated in a mouse infection
model, it induced an immune response identical to virulent TB
[150,151]. Researchers at the Albert Einstein College of Medicine
(NY, USA) have generated two triple mutants, mc26020 and
mc26030, that were highly attenuated and safer than BCG in
severe combined immunodeficiency mice [152–155]. While both
strains are panthothenate auxotrophs, the former is also a lysine
auxotroph, while the latter has a deletion in the RD1 locus
implicated in the attenuation of BCG. Both strains are cur-
rently undergoing Phase I clinical trials. Recently, a mutant
with an unusual persistence phenotype has been identified: a
kasB mutant that synthesized shorter mycolic acids was shown
to persist in immunocompetent mice for up to 1 year without
causing disease and the pathology associated with it [156], sug-
gesting that kasB would be a good candidate for deletion in a
future live TB vaccine strain.
Nonbacterial vaccines
Direct immunization with immunogenic M. tuberculosis poly-
peptides has been tested as an alternative: antigen 85A, ESAT-6
protein from the RD1 locus and the PPE family proteins
Mtb39a-e and Mtb41 have all been assessed as candidates [139]. A
‘hybrid’ approach has also been used, wherein recombinant
fusions of these polypeptides were used to assess protection in
animal models [157,158]. Many of these are currently under
Phase I clinical trials. Another strategy is injection of naked
(plasmid) DNA encoding immunogenic M. tuberculosis anti-
gens, which has been used to elicit a response against the bacte-
rium in mouse and guinea pig models of infection [159]. Recom-
binant polypeptides and DNA vaccines have also been used in a
‘prime–boost’ strategy that involves vaccination with BCG or
recombinant BCG, followed by a booster of selected antigen(s)
that are also common to the ‘prime’ [139]. A novel approach has
been used by researchers at Oxford University (UK) making use
of the boosting potential of a modified vaccinia Ankara virus.
The recombinant virus expressing Ag85A when used as a boost
provided greater protection than BCG or recombinant virus
alone [160,161].
Lipid antigens
Similarities to MHC class I molecules and expression on anti-
gen-presenting cells suggested a role for CD1 molecules in
T-cell recognition. CD1 isoforms, CD1a and CD1c, were
established as targets for recognition by αβ- and γδ-cytotoxic
T-lymphocyte lines, respectively [162]. Studies of the prolifera-
tive and cytotoxic responses of an αβ-TCR+ CD4-CD8- T-cell
line specific for an undefined M. tuberculosis antigen indicated
recognition was absolutely dependent on the presence of CD1b
on the presenting cell, providing direct evidence for CD1-
mediated antigen presentation and suggesting a role for CD1 in
antimicrobial immunity [163].
The first evidence that CD1-presented antigens differed from
their MHC-presented counterparts was provided through stud-
ies on CD1b-restricted αβ-TCR+ T-cell lines specific for
M. tuberculosis; CD1b-restricted recognition was insensitive to
prior protease treatment of the M. tuberculosis antigen. Frac-
tionation of organic solvent extracts of mycobacteria revealed
that the CD1b-restricted antigen was mycolic acid [164], subse-
quent studies have defined other microbial lipids as antigens
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presented by the group 1 molecules CD1b [165–167], CD1c [168]
and CD1a [169] and, more recently, by the group 2 molecule
CD1d [170–175], and support the idea that CD1 molecules pre-
dominantly present lipid antigens. Mycobacteria, including
M. tuberculosis, have an especially rich repertoire of complex
bioactive lipids and the group 1 CD1 isotypes are upregulated
by exposure to these, including mannosyl-β-1-phosphomy-
coketides [168], diacylated sulphoglycolipid [167] and glucose
monomycolate [176], while downregulation of CD1d is appar-
ent on mycobacterial infection [177]. There is little evidence for
an important role for CD1d presentation of lipid antigens in
mycobacterial infection in mice [178]; these animals only possess
a single CD1 isoform most closely related to human CD1d and
thus their utility to understanding the role of CD1-presented
antigens in the development of protective immunity is some-
what limited. The use of animal models that possess analogues
of the other human CD1 isoforms, such as guinea pigs [179],
may prove very useful in understanding the role of lipid anti-
gens in the development of protective immunity [178]. Hiro-
matsu et al. demonstrated that CD1-restricted responses could
be generated in vivo by immunization of guinea pigs with
mycobacterial glycolipids, providing support for their use as a
relevant small animal model for the study of CD1-restricted
immune responses to mycobacterial pathogens [180]. Further-
more, these authors provided evidence that guinea pigs vacci-
nated with a protein-free heterogeneous mycobacterial lipid
extract showed reduced bacterial burdens in the lung and
spleen at 4 weeks after infection by an aerosol challenge and
also had significantly less necrotic pathology [181]. These limited
data support an important role for lipid antigens in the
immune response to M. tuberculosis infection and their further
study to determine whether their inclusion in subunit vaccines
might enhance their efficacy.
Conclusion
The recent increase in TB cases forced the WHO to declare
TB a global emergency. The emergence of multidrug resist-
ance, now superseded by extensive drug resistance, has com-
pounded the healthcare problem. Fears regarding the effective
redundancy of several antimycobacterial drugs stresses the
need for identification of new drug targets and development
of new drugs, several of which are now under clinical evalua-
tion. In addition, given that the current BCG vaccine is
highly variable in its efficacy, control of TB would be helped
with a newer, more effective vaccine. Significant research
efforts have been applied to the development of efficient
agents to be used in both immunoprophylaxis and chemo-
therapy. A number of new drug candidates outlined in this
review show promise against not just existing targets but also
new ones. Also, although a multipronged approach is being
used to develop new vaccines, all candidates are currently in
different stages of clinical trials and there is not yet a clear
candidate for replacing BCG.
Expert commentary
Despite current therapies being based on drugs that have been
available for decades with few additions, the recent and
increased research effort into TB chemotherapeutics has pro-
duced a stream of new molecules in clinical and preclinical
assessment that might at least be useful in the treatment of
drug-resistant TB. Several have excellent extended EBA and
may ultimately improve the global healthcare outlook by allow-
ing the shortening of anti-TB chemotherapy. Several of these
new drugs represent extremely good candidates as they act
against novel targets and thus avoid issues of crossresistance
with others drugs. We are of the opinion that there is great util-
ity in continuing to define the modes of action of several pre-
existing drugs. Although the recent determination of the mode
of action of ETH was disappointing in that it was revealed to
be identical to that for INH, save for a different enzymic route
to prodrug activation [182], other agents, such as isoxyl and thi-
acetazone, are still to have their modes of action completely
defined [183], although these probably both target the meromy-
colic acid-elongation processes in the biosynthesis of mycolic
acid and their cyclopropanation, respectively [184]. Progress
here, and elsewhere, is likely to highlight novel enzymes for
development of possibly better lead compounds. Controversy
surrounds the search for new drugs that inhibit M. tuberculosis
cell wall synthesis. It is felt that adding new drugs that act on
actively growing M. tuberculosis will only help with treating
MDR organisms (admittedly an increasing problem) but may
do little to address the main problem, the length of time of
treatment, which is essentially defined by persistent popula-
tions. Some argue that cell wall synthesis may be already defec-
tive or unnecessary in these organisms as they are not stainable
or otherwise detectable microscopically [185]. We, however,
would strongly argue in support of the need for new drug tar-
gets and inhibitors that target the mycobacterial cell wall. Since
their discovery in the 1950s, inhibitors of cell wall synthesis
have been the mainstay of many chemotherapeutic regimens.
Agents, such as INH, an inhibitor of mycolic acid biosynthesis,
when implemented into directly observed therapies have
proved highly successful in combating drug-sensitive TB. How-
ever, a key issue is the spread of MDR-TB. As a result, the
search for new drug targets and cheap alternative agents is
greatly needed. While drugs that target nonreplicating forms
appear desirable on theoretical grounds, we cannot predict how
new drugs will impact on time to cure and we need to await
clinical trial data before drawing any such conclusions. Also,
the challenge of drug resistance and adverse drug reactions
means that, in a significant number of cases, we are searching
for cheap yet effective alternative agents. As a result, there will
always be a place for new drugs in these areas, with cell wall
inhibitors being highly profitable in the past.
The variable efficacy of BCG requires that several avenues of
vaccine research must be pursued. T-cell responses specific for
foreign lipid antigens presented by CD1 molecules are clearly
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important components of the host response to microbial infec-
tion, especially for pathogens such as M. tuberculosis that have
adapted to an intracellular existence in the endosomal compart-
ment and are therefore poor targets for humoral immunity.
Current evidence suggests that CD1-restricted responses may
make significant contributions to protective immunity in
guinea pigs and eventually inclusion of lipid antigens might
contribute to the formulation of improved vaccines [180,181].
Further studies in animal models that closely reflect the profile
of human CD1 isoforms will probably clarify their importance.
Establishing the structures of such CD1-restricted lipid anti-
gens and the molecular and immunological basis of their gener-
ation and recognition may become key to the development of
novel therapeutic approaches.
Five-year view
The anti-TB ‘pipeline’ is currently awash with new clinical and
preclinical candidate drugs. Several of these will have utility at
least in the management of MDR/XDR-TB and some may even
have sufficient potency to allow the shortening and simplifica-
tion of current regimens. In the coming years, as we increase our
knowledge regarding the metabolism of M. tuberculosis and,
more specifically, of the problematic persistent populations, key
enzymes worthy of future investigation as novel drug targets will
probably come to light. Pursuing their characterization and
designing and developing inhibitors might afford us new tools
with which to combat these long-standing adversaries.
The great structural diversity of microbial lipids and the lim-
ited number of defined antigens to date suggests we are only at
the very beginning of a journey towards understanding the
structural basis for CD1-restricted lipid antigen presentation.
As more antigens are defined, an improved understanding of
their relative immunodominance during infection in appro-
priate models, as well as the kinetics of lipid-specific T-cell
responses and their correlation with susceptibility to disease,
will become critical to their candidacy as components of
developmental vaccines.
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Key issues
• TB remains a major global healthcare concern.
• Latent infections can last decades before active 
disease develops.
• Latent infection represents a huge global reservoir of infection.
• Extensive drug resistance is emerging.
• Several new drugs are in development, many of which disrupt 
ATP synthesis.
• The current bacillus Calmette–Guerin vaccine is, at best, 
variable in its efficacy.
• Preventative and prophylactic vaccines are under development, 
particularly focused towards improved clearance of 
latent infection.
• Lipid antigens represent an interesting avenue for future 
vaccine development.
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